Navigation Links
Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
Date:4/17/2008

BEIJING, April 17 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (''Lotus'' or the ''Company''), a pharmaceutical company in the People's Republic of China ("PRC"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2007.

Fourth Quarter 2007 Highlights

-- Total revenues increased to $19.2 million, up 72.7% from the fourth

quarter of 2006

-- Gross profit reached $8.3 million, up 234% from the fourth quarter of

2006

-- Gross margin was 43.1%, up from 22.3% in the fourth quarter of 2006

-- Operating income totaled $3.4 million, up from a loss of $0.1 million

in the fourth quarter of 2006

-- Net income increased to $5.1 million, or $0.12 per diluted share, up

from a loss of $0.2 million, or ($0.00) per diluted share, in the

fourth quarter of 2006

-- Excluding non-cash debt financing costs and a gain from the forgiveness

of income and value-added taxes, adjusted net income was $3.4 million,

or $0.08 per fully diluted share

Full Year 2007 Highlights

-- Total revenues increased 57% in 2007 to $56.9 million

-- Gross profit increased 130% in 2007 to $23.2 million

-- Gross margin was 40.8%, up from 27.8% in 2006

-- Operating income increased 153% to $11.3 million

-- Net income increased to $11.2 million, or $0.26 per fully diluted share,

up from $4.1 million, or $0.10 per fully diluted share in 2006

-- Excluding non-cash debt financing costs and one-time financial items,

adjusted net income was $8.5 million, or $0.19 per fully diluted share,

up 34.3% from adjusted net income in 2006

''This was a very successful year for Lotus Pharmaceuticals, both in terms of financial performance and the execution of our strategic initiatives. We achieved significant growth in revenues, due in large part to our strateg $ --

Accounts payable and accrued

expenses 764,491 705,147

VAT and service taxes payable 572,200 2,047,851

Advances from customers 34,531 231,340

Unearned revenue 530,063 426,358

Due to related parties 323,178 925,484

Total current liabilities 4,786,108 4,336,180

LONG-TERM LIABILITIES:

Due to related parties 738,300 863,447

Notes payable - related parties 4,738,508 4,729,880

Total Liabilities 10,262,916 9,929,507

Stockholders' Equity

Common stock ($.001 par value;

200,000,000 shares authorized;

41,794,200 and 41,280,000 shares

issued and outstanding, respectively) 41,794 41,280

Additional paid-in capital 8,095,848 5,965,323

Statutory reserves 2,161,505 769,930

Retained earnings 14,355,913 4,530,360

Other comprehensive gain - 1,981,557 501,205

cumulative foreign currency

translation adjustment

Total stockholders' equity 26,636,617 11,808,098

Total Liabilities and Shareholders'

Equity $ 36,899,533 $ 21,737,065

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Year Ended

December 31,

2007 2006

(restated)

CASH FLOWS FROM OPERATING

ACTIVITIES:

Net income $11,217,128 $4,143,020

Adjustments to reconcile net income

from operations to net cash provided

by (used in) operating activities:

Depreciation and amortization 564,607 581,564

Amortization of deferred debt

issuance costs 205,379 --

Amortization of debt discount 1,458,484 --

Stock issued for compensation 284,200 --

(Decrease) increase in allowance

for doubtful accounts and sales

returns (2,385,354) 2,732,889

Forgiveness of income and

value-added taxes (2,160,795) --

Changes in assets and liabilities:

Accounts receivable (9,764,076) (8,922,247)

Inventories (58,942) 3,928,236

Prepaid and other current assets (714,013) (75,155)

Other payable -- --

Accounts payable and accrued expenses 27,266 206,516

Value-added and service taxes payable 608,526 1,999,675

Unearned revenue 71,402 200,811

Advances from customers (204,267) 39,333

NET CASH (USED IN) PROVIDED BY

OPERATING ACTIVITIES (850,455) 4,834,642

CASH FLOWS FROM INVESTING

ACTIVITIES:

Collections from related party

advances 1,061,009 1,243,742

Purchase of property and equipment (381,772) (1,480)

NET CASH PROVIDED BY INVESTING

ACTIVITIES 679,237 1,242,262

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from convertible debt 2,950,000 --

Payment of debt issuance costs (231,526) --

Repayments of related party advances (816,732) (737,291)

Repayments of notes payable

- related parties 509,351 (3,456,196)

NET CASH PROVIDED BY (USED IN)

FINANCING ACTIVITIES 2,411,093 (4,193,487)

NET INCREASE IN CASH 2,239,875 1,928,222

EFFECT OF EXCHANGE RATE ON CASH 228,926 44,805

CASH - beginning of year 2,089,156 160,934

CASH - end of year $4,557,957 $2,089,156

SUPPLEMENTAL DISCLOSURE OF CASH

FLOW INFORMATION:

Cash paid for:

Interest $477,001 $325,824

Income taxes $-- $--

Non-cash investing and

financing activities:

Due from related party offset

against note payable - related

parties $813,650 $--

Common stock issued for conversion

of convertible debt $230,000 $--

Debt discount for grant of warrants

and beneficial conversion feature $1,616,839 $--

Intangible assets for related

party liabilities $-- $1,127,551

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL DATA

For the Three Months For the Three Months

Ended Ended

Adjusted Net income December 31, 2007 December 31, 2006

($ in thousands except

per share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 3,431,557 0.08 2,042,291 0.05

Adjustments

Non cash debt financing

costs(1) (475,390) (0.01) --

Allowance for sales returns(2) -- -- (2,200,000) (0.05)

Forgiveness of income and

value-value added taxes(3) 2,160,795 0.05 --

Amount per consolidated

statement of operations 5,116,962 0.12 (157,709) 0.00

(1) Non cash debt financing costs for 2007 includes amortization of debt

issue costs of $58,680 and amortization of debt discount of $416,710

(2) Allowance for sales returns related to products sold in the fourth

quarter of 2006 and recognized in the second and third quarter of

2007

(3) Tax waiver from the Chinese local government

For the Year ended For the Year ended

Adjusted Net income December 31, 2007 December 31, 2006

($ in thousands except

per share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 8,520,196 0.19 6,343,020 0.16

Adjustments

Non cash debt financing

costs(1) (1,663,863) (0.04) -- --

Allowance for sales returns(2) 2,200,000 0.05 (2,200,000) 0.06

Forgiveness of income and

value-value added taxes(3) 2,160,795 0.05 -- --

Amount per consolidated

statement of operations 11,217,128 0.26 4,143,020 0.10

(1) Non cash debt financing costs for 2007 includes amortization of debt

issue costs of $205,379 and amortization of debt discount of

$1,458,484

(2) Allowance for sales returns related to products sold in the fourth

quarter of 2006

(3) Tax waiver from the Chinese local government

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Tel: +1-877-801-0344

Email: info@LotusEast.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

y of penetrating the direct sales channels into agencies and hospitals and enhancing our production capacity. We also focused on our best selling products, including our hypertension medication VALSARTAN Capsules, and began distributing higher-margin, third-party pharmaceutical products through our existing network,'' said Mr. Zhongyi Liu, Chairman and CEO of Lotus Pharmaceuticals, Inc. ''We will continue to maintain this strategy in the year ahead and plan to explore new markets.''

Fourth Quarter 2007 Results

Lotus Pharmaceutical's total revenue in the fourth quarter was $19.2 million, an increase of 73% on year-over-year basis. This was primarily the result of strong performance associated with the Company's continued efforts to develop its sales distribution channels. Wholesale revenue increased 143% year-over-year to $15.9 million, or 83% of total revenue, and includes the effect of the recording of a $2.2 million sales return allowance in 2006, which reduced 2006 revenues. Other revenue decreased 24% year-over-year to $3.1 million, or 16% of revenue in the fourth quarter of 2007, mainly due to a decrease in third-party manufacturing. Retail revenue was $0.2 million in the fourth quarter of 2007, due to the Company's strategy to sell its traditional Chinese medicines at reduced prices through its retail channel due to quality control concerns.

Gross profit in the fourth quarter of 2007 was $8.3 million, an increase of 234% on year-over-year basis. Gross margin was 43.1%, up from 22.3% in the fourth quarter of 2006, primarily due to production efficiencies as well as the recording of a sales allowance in the fourth quarter of 2006, which decreased revenue by $2.2 million.

Operating expenses in the fourth quarter of 2007 were $4.8 million, up 85% from $2.6 million in the fourth quarter of 2006. This increase was primarily the result of higher selling expenses associated with the Company's sales growth. Research and development expenses were $0.9 million in the fourth quarter of 2007, compared with $0.1 in the fourth quarter of 2006. General and administrative expenses were $0.4 million, down from $0.7 million a year ago. Operating expenses were 25% of total revenue in the fourth quarter of 2007, up from 24% in the fourth quarter of 2006.

Operating income was $3.4 million, compared with an operating loss of $0.1 million in the fourth quarter of 2006.

Net income for the fourth quarter of 2007 was $5.1 million, or $0.12 per diluted share, compared to loss of $0.1 million, or ($0.00) per fully diluted share, in the fourth quarter of 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, and a one-time forgiveness of income and value added taxes of $2.2 million, adjusted net income was $3.4 million, or $0.08 per fully diluted share, in the fourth quarter of 2007, up 68% from adjusted net income of $2.0 million, or $0.05 per fully diluted share, in the fourth quarter of 2006.

Full Year 2007 Results

For the full year 2007, total revenues were $56.9 million, up 57% from $36.2 million in 2006. Wholesale revenue increased 64% in 2007 $41.7 million, or 73% of total revenue, and includes the effect of a $2.2 million reversal of a sales return allowance originally recorded in 2006. Other revenue increased 62% in 2007 to $11.8 million, or 21% of revenue in 2007. Retail revenue was relatively unchanged at $3.5 million. Gross profit for the full year 2007 was $23.2 million, an increase of 130% from $10.1 million in 2006. Gross margin was 40.8%, up from 27.8% in 2006. Operating income was $11.3 million, up 153% from $4.5 million in 2006. Net income for 2007 was $11.2 million, or $0.26 per diluted share, compared to $4.1 million, or $0.10 per diluted share, in 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, the previously mentioned one-time reversal of a sales allowance and a one-time forgiveness of income and value added taxes, adjusted net income was $8.5 million, or $0.19 per fully diluted share, in 2007, up 34% from adjusted net income of $6.3 million, or $0.16 per fully diluted share, in 2006.

Financial Condition

As of December 31, 2007, Lotus had $4.6 million in cash and equivalents, approximately $24.7 million in working capital, secured convertible notes of $2.6 million and $4.7 million in notes payable. Stockholders' equity at December 31, 2007 was $26.6 million, up 126% from $11.8 million at December 31, 2006.

In 2008 the Company received net proceeds from the sale of shares of its Series A Convertible Redeemable Preferred Stock of approximately $4.6 million. The Company used approximately $2.6 million to repay in full all of its outstanding obligations under its 14% secured convertible notes, the remainder will be used for working capital purposes.

2008 Outlook

''In 2008, we expect to see continued growth in sales and anticipate a growing contribution from sales of our proprietary products. We plan to utilize the capital raised in our private placement to fund our exciting new R&D initiatives and to strengthen our sales channels. Additionally, we plan to diversify our products,'' said Mr. Liu. ''We recently completed a $5.0 million private placement financing which provides us with the resources we need to pursue our R&D efforts and pursue strategic acquisitions. Additionally, we plan to use our sales and marketing expertise and the benefits of scale to improve profitability. We believe we are in a very strong position to take advantage of the growing pharmaceutical market in China, and are committed to maximizing value to our shareholders now and in the future.''

Conference Call

The Company will conduct a conference call at 9:00 a.m. Eastern Time on Thursday, April 17, 2008 to discuss the fourth quarter and fiscal year 2007 results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 800-688-0796. International callers should dial 617-614-4070. The Conference ID for this call is 615 756 86. If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, April 17, 2008 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, conference ID 35016441.

Use of Non-GAAP Financial Information

GAAP results for the three and twelve month periods ended December 31, 2007 and December 21, 2006 include certain non-cash debt financing expenses related to the Company's convertible notes, a $2.2 million one-time reversal of a sales allowance in 2007 that was originally recorded in the fourth quarter of 2006 and a one-time tax relief of $2.2 million recorded in the fourth quarter of 2007. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information, which are adjusted net income and adjusted earnings per share, excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears below. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. (''Lotus'') controls and operates Liangfang Pharmaceutical, Ltd. (''Liangfang'') and Enzhe Jiashi Pharmaceutical, Ltd. (''En zhe''), two Chinese pharmaceutical companies located in Beijing (together ''Lotus East''). Lotus East is a comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. The Company possesses some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Lotus East, and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines through 10 retail pharmacy location through Beijing. For more information, visit http://www.LotusEast.com .

Safe Harbor Statement

Certain statements set forth in this press release constitute ''forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," ''would,'' ''may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

-- FINANCIAL TABLES FOLLOW --

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Unaudited Consolidated Statements of Operations

Three Months Ended December 31,

2007 2006

(restated)

Revenues $ 19,223,779 $ 11,128,000

Cost of Goods Sold 10,940,507 8,647,623

Gross Profit 8,283,272 2,480,377

Operating Expenses

Selling 3,595,460 1,839,251

Research and development 862,519 96,833

General and administrative 382,646 684,888

Total operating expenses 4,840,625 2,620,972

Income (Loss) from Operations 3,442,647 (140,595)

Other Income (Expense)

Other income (expense) 2,102,115 --

Interest expense, net (427,800) (17,114)

Total other income (expense) 1,674,315 (17,114)

Income (Loss) Before Provision

for Income Tax 5,116,962 (157,709)

Net Income (Loss) $ 5,116,962 $ (157,709)

Basic Earnings Per Share $ 0.12 $ (0.00)

Diluted Earnings Per Share $ 0.12 $ (0.00)

Basic Weighted Average Shares

Outstanding 41,678,330 41,280,000

Diluted Weighted Average Shares

Outstanding 44,448,330 44,280,000

The Components of Other

Comprehensive

Income

Net Income (Loss) $ 5,116,962 $ (157,709)

Foreign currency translation

adjustment 927,537 130,223

Comprehensive Income (Loss) $ 6,044,499 $ (27,486)

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Audited Consolidated Statements of Operations

Years Ended December 31,

2007 2006

(restated)

Revenues $ 56,873,115 $ 36,207,689

Cost of Goods Sold 33,678,963 26,129,687

Gross Profit 23,194,152 10,078,002

Operating Expenses

Selling 6,460,206 3,030,4216

General and administrative 3,014,002 2,191,400

Research and development 2,411,651 387,337

Total operating expenses 11,885,859 5,609,158

Income from operations 11,308,293 4,468,844

Other Income (Expense)

Other income 1,845,416 --

Interest expense, net (1,936,581) (325,824)

Total other income (expense) (91,165) (325,824)

Net Income Before Provision for

Income Tax 11,217,128 4,143,020

Net Income $ 11,217,128 $ 4,143,020

Basic Earnings Per Share $ 0.27 $ 0.10

Diluted Earnings Per Share $ 0.26 $ 0.10

Basic Weighted Average Shares

Outstanding 41,417,434 40,360,530

Diluted Weighted Average Shares

Outstanding 43,861,106 40,360,530

The Components of Other

Comprehensive Income

Net Income $ 11,217,128 $ 4,143,020

Foreign currency translation

adjustment 1,480,352 327,568

Comprehensive Income $ 12,697,480 $ 4,470,588

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Audited Consolidated Balance Sheets

December 31, 2007 and 2006

2007 2006

Current Assets (restated)

Cash and cash equivalents $ 4,557,957 $ 2,089,156

Accounts receivable, net 20,430,827 7,277,067

Inventories 3,410,739 3,133,677

Prepaid expenses 1,009,382 252,103

Deferred debt costs 29,340 --

Total current assets 29,438,245 12,752,003

Property and equipment, net 6,169,966 5,813,935

Intangible assets, net 1,291,322 1,345,041

Due from related party -- 1,826,626

Total Assets $ 36,899,533 $ 21,737,605

LIABILITIES AND STOCKHOLDERS'

EQUITY

Current Liabilities

Convertible debt, net of debt

discount $ 2,561,645
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
2. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
3. Lotus Pharmaceuticals Raises $5 Million in Private Placement
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
11. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published ... rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin ... a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... Overland Park, KS (PRWEB) , ... February 08, 2016 , ... ... Oils, a leader in Mole removal products. , Moles are derived from a cluster ... can appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in ... Red Day. National Wear Red Day is the first Friday each February and ... and stroke cause 1 in 3 deaths among women each year – more than ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... year-end 2015 results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 11, 2016 at 4:30 p.m. Eastern Time (1:30 p.m. ... http://www.neurocrine.com . --> Participants can access the ...
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... announced the addition of the "Global Skin ... offering. --> Research and ... of the "Global Skin Protective Equipment Market ...
(Date:2/8/2016)... --  Intarcia Therapeutics, Inc. today announced the appointment ... newly created role of Vice President, Head of Global ... decades of leadership experience at leading pharmaceutical, biotechnology, and ... center. Most recently Dr. Yee served as VP, Head ... Medical Officer at AstraZeneca, where he led medical affairs ...
Breaking Medicine Technology: